NASDAQ · ZBIO

Zenas BioPharma, Inc.

$30.39 -$0.60 (-1.94%) 1D After hours
Charting by TradingView

Key Metrics

$1.96B
Market cap
—
P/E · TTM
$10.00M
Revenue · TTM
−$425.15M
Net income
EPS · TTM $-10.17
Dividend yield —
Free cash flow −$210.48M
Beta · 1Y 1.23
EBITDA · TTM −$423.04M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 25
    The stock moved +13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 25
  • May 18
    From its Feb 19 high, the share price fell 37%.

    Peak close $27.02 on Feb 19; trough close $16.91 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37%
  • Mar 27
    The stock moved -17.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.96B
Enterprise value—
Shares outstanding63.1M
52-wk range$13.50 – $44.60
Avg volume · 20D445.2K
Net cash —
Book value / share$8.03
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Zenas BioPharma, Inc.
IPO dateSep 13, 2024
Employees167

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S195.65
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating -4,230.8%
Net -4,251.5%
FCF -2,104.8%
ROE / ROIC -131.2% · 110.9%

Financial Health

Current ratio11.94
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$669.00M

Cash Flow · TTM

Operating CF −$210.48M
Capex −$2.00K
Free cash flow −$210.48M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings